Abstract
Development of acquired resistance to gefitinib after an initial good response is common. Recently, it was reported that this acquired resistance is related to a secondary mutation associated with a substitution of threonine by methionine at codon 790 (T790M) of the epidermal growth factor receptor (EGFR) gene. In this report, we present a "never smoking" woman with advanced lung cancer who showed acquired resistance to gefitinib, and analysis of autopsy samples revealed no evidence of EGFR mutations in either exons 18-21 or codon 790, and positive immunostaining for breast cancer resistance protein (BCRP). We describe, for the first time, a case in which expression of BCRP was associated with acquired resistance to gefitinib, independent of EGFR mutations.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
ATP-Binding Cassette Transporters / genetics*
-
Aged
-
Antineoplastic Agents / therapeutic use*
-
Autopsy
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology
-
Drug Resistance, Neoplasm*
-
Fatal Outcome
-
Female
-
Gefitinib
-
Humans
-
Immunohistochemistry
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology
-
Neoplasm Proteins / genetics*
-
Quinazolines / pharmacology
-
Quinazolines / therapeutic use*
-
Radiography, Thoracic
-
Smoking*
-
Tomography, X-Ray Computed
Substances
-
ABCG2 protein, human
-
ATP Binding Cassette Transporter, Subfamily G, Member 2
-
ATP-Binding Cassette Transporters
-
Antineoplastic Agents
-
Neoplasm Proteins
-
Quinazolines
-
Gefitinib